5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Sell
14
APDN Quote, Financials, Valuation and Earnings
Last price:
$0.84
Seasonality move
:
-10.76%
Day range:
$0.79 - $0.87
52-week range:
$0.72 - $236.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.05x
P/B ratio:
0.08x
Volume:
116.3K
Avg. volume:
1.2M
1-year change:
-99.55%
Market cap:
$956.8K
Revenue:
$3.4M
EPS (TTM):
-$285.99
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
$1.2M | -$3.00 | 27.47% | -98.87% | -- |
|
FONR
Fonar
|
-- | -- | -- | -- | -- |
|
OCX
OncoCyte
|
$126.8K | -$0.25 | -27.97% | -77.88% | $4.42 |
|
PRPH
ProPhase Labs
|
$2.5M | -$0.18 | -32.58% | -48.57% | $13.80 |
|
VCYT
Veracyte
|
$111M | $0.20 | 14.14% | -93.75% | $41.50 |
|
XWEL
XWELL
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
$0.87 | -- | $956.8K | -- | $0.00 | 0% | 0.05x |
|
FONR
Fonar
|
$12.31 | -- | $77.9M | 10.70x | $0.00 | 0% | 0.78x |
|
OCX
OncoCyte
|
$2.83 | $4.42 | $80.9M | -- | $0.00 | 0% | 19.66x |
|
PRPH
ProPhase Labs
|
$0.29 | $13.80 | $12M | -- | $0.00 | 0% | 0.86x |
|
VCYT
Veracyte
|
$30.84 | $41.50 | $2.4B | 102.80x | $0.00 | 0% | 5.38x |
|
XWEL
XWELL
|
$0.82 | -- | $4.3M | -- | $0.00 | 0% | 0.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
-- | 5.301 | -- | 4.28x |
|
FONR
Fonar
|
0.03% | 1.233 | 0.07% | 10.85x |
|
OCX
OncoCyte
|
-- | -1.798 | -- | 1.41x |
|
PRPH
ProPhase Labs
|
31.06% | -4.436 | 37.21% | 1.12x |
|
VCYT
Veracyte
|
-- | 3.551 | -- | 4.27x |
|
XWEL
XWELL
|
-- | -0.848 | -- | 1.72x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
$684.1K | -$3M | -113.07% | -113.07% | -247.7% | -$3.4M |
|
FONR
Fonar
|
$9.7M | $2.4M | 4.95% | 4.95% | 11.92% | $1.5M |
|
OCX
OncoCyte
|
$595K | -$5.4M | -581.11% | -581.11% | -2253.1% | -$5.6M |
|
PRPH
ProPhase Labs
|
-$165K | -$7.9M | -47.22% | -59.59% | -252.29% | -$4.2M |
|
VCYT
Veracyte
|
$78.8M | $6M | 2.14% | 2.14% | 2.9% | $20.4M |
|
XWEL
XWELL
|
$2.1M | -$4.6M | -71.82% | -71.82% | -54.82% | -$3.8M |
Applied DNA Sciences vs. Competitors
-
Which has Higher Returns APDN or FONR?
Fonar has a net margin of -220.57% compared to Applied DNA Sciences's net margin of 7.87%. Applied DNA Sciences's return on equity of -113.07% beat Fonar's return on equity of 4.95%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences57.17% -$28.00 $12.5M FONRFonar39.03% $0.29 $159M -
What do Analysts Say About APDN or FONR?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 172950.3%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Applied DNA Sciences has higher upside potential than Fonar, analysts believe Applied DNA Sciences is more attractive than Fonar.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 FONRFonar0 0 0 -
Is APDN or FONR More Risky?
Applied DNA Sciences has a beta of 0.405, which suggesting that the stock is 59.491% less volatile than S&P 500. In comparison Fonar has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.30600000000001%.
-
Which is a Better Dividend Stock APDN or FONR?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or FONR?
Applied DNA Sciences quarterly revenues are $1.2M, which are smaller than Fonar quarterly revenues of $25M. Applied DNA Sciences's net income of -$2.6M is lower than Fonar's net income of $2M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while Fonar's PE ratio is 10.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.05x versus 0.78x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.05x -- $1.2M -$2.6M FONRFonar0.78x 10.70x $25M $2M
-
Which has Higher Returns APDN or OCX?
OncoCyte has a net margin of -220.57% compared to Applied DNA Sciences's net margin of -2255.11%. Applied DNA Sciences's return on equity of -113.07% beat OncoCyte's return on equity of -581.11%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences57.17% -$28.00 $12.5M OCXOncoCyte40.04% -$1.93 -$12.3M -
What do Analysts Say About APDN or OCX?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 172950.3%. On the other hand OncoCyte has an analysts' consensus of $4.42 which suggests that it could grow by 56.07%. Given that Applied DNA Sciences has higher upside potential than OncoCyte, analysts believe Applied DNA Sciences is more attractive than OncoCyte.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 OCXOncoCyte1 2 0 -
Is APDN or OCX More Risky?
Applied DNA Sciences has a beta of 0.405, which suggesting that the stock is 59.491% less volatile than S&P 500. In comparison OncoCyte has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.749%.
-
Which is a Better Dividend Stock APDN or OCX?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or OCX?
Applied DNA Sciences quarterly revenues are $1.2M, which are smaller than OncoCyte quarterly revenues of $1.5M. Applied DNA Sciences's net income of -$2.6M is higher than OncoCyte's net income of -$33.5M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.05x versus 19.66x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.05x -- $1.2M -$2.6M OCXOncoCyte19.66x -- $1.5M -$33.5M
-
Which has Higher Returns APDN or PRPH?
ProPhase Labs has a net margin of -220.57% compared to Applied DNA Sciences's net margin of -209.38%. Applied DNA Sciences's return on equity of -113.07% beat ProPhase Labs's return on equity of -59.59%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences57.17% -$28.00 $12.5M PRPHProPhase Labs-5.25% -$0.35 $55.3M -
What do Analysts Say About APDN or PRPH?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 172950.3%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 4725.18%. Given that Applied DNA Sciences has higher upside potential than ProPhase Labs, analysts believe Applied DNA Sciences is more attractive than ProPhase Labs.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 PRPHProPhase Labs0 0 0 -
Is APDN or PRPH More Risky?
Applied DNA Sciences has a beta of 0.405, which suggesting that the stock is 59.491% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.472, suggesting its less volatile than the S&P 500 by 147.175%.
-
Which is a Better Dividend Stock APDN or PRPH?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or PRPH?
Applied DNA Sciences quarterly revenues are $1.2M, which are smaller than ProPhase Labs quarterly revenues of $3.1M. Applied DNA Sciences's net income of -$2.6M is higher than ProPhase Labs's net income of -$6.6M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.05x versus 0.86x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.05x -- $1.2M -$2.6M PRPHProPhase Labs0.86x -- $3.1M -$6.6M
-
Which has Higher Returns APDN or VCYT?
Veracyte has a net margin of -220.57% compared to Applied DNA Sciences's net margin of 4.31%. Applied DNA Sciences's return on equity of -113.07% beat Veracyte's return on equity of 2.14%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences57.17% -$28.00 $12.5M VCYTVeracyte66.39% $0.06 $1.2B -
What do Analysts Say About APDN or VCYT?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 172950.3%. On the other hand Veracyte has an analysts' consensus of $41.50 which suggests that it could grow by 36.84%. Given that Applied DNA Sciences has higher upside potential than Veracyte, analysts believe Applied DNA Sciences is more attractive than Veracyte.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 VCYTVeracyte7 2 1 -
Is APDN or VCYT More Risky?
Applied DNA Sciences has a beta of 0.405, which suggesting that the stock is 59.491% less volatile than S&P 500. In comparison Veracyte has a beta of 2.145, suggesting its more volatile than the S&P 500 by 114.466%.
-
Which is a Better Dividend Stock APDN or VCYT?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or VCYT?
Applied DNA Sciences quarterly revenues are $1.2M, which are smaller than Veracyte quarterly revenues of $118.6M. Applied DNA Sciences's net income of -$2.6M is lower than Veracyte's net income of $5.1M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while Veracyte's PE ratio is 102.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.05x versus 5.38x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.05x -- $1.2M -$2.6M VCYTVeracyte5.38x 102.80x $118.6M $5.1M
-
Which has Higher Returns APDN or XWEL?
XWELL has a net margin of -220.57% compared to Applied DNA Sciences's net margin of -56.4%. Applied DNA Sciences's return on equity of -113.07% beat XWELL's return on equity of -71.82%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences57.17% -$28.00 $12.5M XWELXWELL24.38% -$0.99 $14.8M -
What do Analysts Say About APDN or XWEL?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 172950.3%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 751.58%. Given that Applied DNA Sciences has higher upside potential than XWELL, analysts believe Applied DNA Sciences is more attractive than XWELL.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 XWELXWELL0 0 0 -
Is APDN or XWEL More Risky?
Applied DNA Sciences has a beta of 0.405, which suggesting that the stock is 59.491% less volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.
-
Which is a Better Dividend Stock APDN or XWEL?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or XWEL?
Applied DNA Sciences quarterly revenues are $1.2M, which are smaller than XWELL quarterly revenues of $8.4M. Applied DNA Sciences's net income of -$2.6M is higher than XWELL's net income of -$4.8M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.05x versus 0.11x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.05x -- $1.2M -$2.6M XWELXWELL0.11x -- $8.4M -$4.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
